Stifel analyst Derek Archila upgraded DBV Technologies to Buy from Hold with a price target of $18, up from $10. The stock in after-hours trading is up 18%, or $2.06, to $13.30. DBV reported three-year PEPITES data, which is suggestive that Viaskin peanut provides increasing levels of protection from peanut exposure with continued treatment beyond one year, Archila tells investors in a research note. The analyst believes the results are “derisking,” particularly in the context of a potential FDA advisory committee. The stock will continue to work into a potential positive FDA panel and approval later this year, says Archila.